A Randomized Study of Interferon α‐2b Versus No Treatment as Consolidation After High Dose Therapy and Autologous Stem Cell Transplantation for Patients With Relapsed Lymphoma

• Published in: The oncologist (Dayton, Ohio) Vol. 18; no. 11; p. 1189
• Main Authors: Bosly, André, Grigg, Andrew, Holte, Harald, Gisselbrecht, Christian, Radford, John, Rossi, Andrea, Lopez‐Guillermo, Armando, Trneny, Marek, Sebban, Catherine, Hagberg, Hans, Leal da Costa, Fernando, Colombat, Philippe, Bron, Dominique, Coiffier, Bertrand
• Format: Journal Article
• Language: English
• Published: Durham, NC, USA AlphaMed Press 2013
• Subjects: Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Clinical Trial Results; Combined Modality Therapy; Consolidation Chemotherapy; Disease Progression; Disease-Free Survival; Female; Humans; Interferon-alpha - therapeutic use; Lymphoma - drug therapy; Lymphoma - surgery; Male; Middle Aged; Prospective Studies; Recombinant Proteins - therapeutic use; Recurrence; Stem Cell Transplantation - methods; Transplantation Conditioning - methods; Transplantation, Autologous

Background. Patients with lymphoma who have experienced a first relapse or progression and have disease deemed sensitive to salvage chemotherapy nevertheless have a high likelihood of having a second relapse. To decrease the likelihood of a second relapse after high‐dose therapy (HDT) and autologous...